Humacyte
HUMA
69 hedge funds and large institutions have $37.4M invested in Humacyte in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 18 closing their positions.
271% more call options, than puts
Call options by funds: $152K | Put options by funds: $41K
49% more capital invested
Capital invested by funds: $25.1M → $37.4M (+$12.4M)
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
0.08% more ownership
Funds ownership: 11.59% → 11.67% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 75 → 69 (-6)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$508K |
| 2 |
State Street
Boston,
Massachusetts
|
+$483K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$344K |
| 4 |
Jane Street
New York
|
+$131K |
| 5 |
UAS
United Asset Strategies
Garden City,
New York
|
+$89.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$589K |
| 2 |
Swiss National Bank
Zurich,
Switzerland
|
-$282K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$222K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$185K |
| 5 |
E
Ergoteles
New York
|
-$157K |
HUMA Hedge Fund Activity: Q1 2023 in Review
69 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q1 2023, worth a combined $37.4M — up 49% from $25.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of HUMA and 12 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 23 added.
The largest buyer was Geode Capital Management, adding an estimated $508K. The largest seller was BlackRock, cutting an estimated $589K.
- 69 institutional investors held Humacyte (HUMA) as of Q1 2023, down from 75 in Q4 2022.
- Funds reported $37.4M of Humacyte stock for Q1 2023, up 49% quarter-over-quarter.
- 12 funds opened new Humacyte positions in Q1 2023 and 18 closed out, a net change of -6 holders.
- The largest Humacyte buyer in Q1 2023 was Geode Capital Management, an estimated $508K added.
- The largest Humacyte seller in Q1 2023 was BlackRock, an estimated $589K sold.
Based on aggregated 13F filings for Q1 2023.